Merck’s investigational antibody MK-2214 has received fast-track designation from the FDA for the treatment of Alzheimer’s disease. MK-2214 targets phosphorylated serine 413 tau (pS413), a marker of ...
Alzheimer’s disease is the most commonly diagnosed form of dementia, but it’s far from the only one. In fact, most people who ...
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the progressive degradation of brain cells, as well ...
New research published in the journal Nature suggests that modest doses of lithium orotate may prevent or even reverse ...
The test confirms the scientific validity of the biomarkers used in the lab, led by researcher Carleara Weiss, and increases ...
MedPage Today on MSN
Year in Review: Alzheimer's Disease
Other noteworthy news in Alzheimer's disease this year included: News about Alzheimer's rose to the forefront in 2025, as the ...
Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...
Regular physical activity in midlife and older adulthood may cut dementia risk by up to 45%, showing it’s never too late to ...
Circular Genomics, Inc., the world-leading developer of circular RNA-based precision medicine tools for neurology and ...
As Alzheimer’s Awareness Month comes to an end, Florida State University researchers are continuing efforts to better ...
Alzheimer's disease symptoms a Mount Sinai neuropsychologist monitors in her own life include missing periods of time and ...
Millions of people are living with Alzheimer's disease, a progressive, irreversible brain disorder that causes cognitive decline, confusion, memory loss, and many other symptoms. The Alzheimer's Assoc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback